Industry 4.0, also known as the Fourth Industrial Revolution (4IR), will result in the digital transformation of the manufacturing sector. It is propelled by transformative trends such as the proliferation of data and connectivity, advancements in analytics, human–machine collaboration, and enhancements in robotics. Biopharmaceutical manufacturers are also giving significant attention to automation and data analytics so as to embrace Industry 4.0. The ultimate objective is to make an automated smart factory, wherein the process operations and control decisions are executed without human supervision. Such a setup offers multiple advantages, such as the ability to perform in-silco optimization as a means of gaining deeper understanding of the underlying physicochemical processes as well as reducing the number of experiments that would be required, ensuring process operation in the design space, real-time monitoring, and process diagnosis and prognosis. Implementation of Industry 4.0 is projected to save time and cost for designing an optimal process, preventing loss of batches and maintaining high consistency of product quality.